What question did this study set out to answer?

This study investigates the clinical relevance of POSTN across multiple cancers, particularly in estrogen receptor-positive breast cancer.

April 19, 2026Scientific Reports1 citationsOpen Access

Pan-cancer characterization of POSTN and its clinical and microenvironmental associations in ER+ breast cancer

XZXiaoyi ZhaiXinjiang Medical University BYBuerlan YeerkenbiekeXinjiang Medical University DYDilinaer YeerxiatiXinjiang Medical University

Key Points

This study investigates the clinical relevance of POSTN across multiple cancers, particularly in estrogen receptor-positive breast cancer.
Integrated public resources including TIMER2.0, TCGA, GTEx, and GEO for analysis.
Performed differential expression and drug-gene association analyses.
Examined immune infiltration and tumor microenvironment features.
Conducted in vitro functional assays to evaluate POSTN's role in cell migration and invasion.
POSTN demonstrated diagnostic and prognostic relevance across various cancers.
Its expression was correlated with tumor microenvironment features, such as macrophages and cancer-associated fibroblasts.
Silencing POSTN reduced the migratory and invasive capacity of ER+ breast cancer cells.
The expression patterns suggested associations with sensitivity or resistance to several small-molecule agents.

Abstract

Periostin (POSTN) is implicated in the progression of multiple malignancies; however, its pan-cancer landscape and clinical relevance in estrogen receptor (ER)-positive breast cancer remain insufficiently characterized. This study aimed to clarify the clinical significance of POSTN via pan-cancer analyses and to further explore its association with ER+ breast cancer. Public resources including Tumor Immune Estimation Resource 2.0 (TIMER2.0), The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO) were integrated to investigate POSTN expression patterns and their associations with prognosis, genetic/epigenetic alterations, tumor microenvironment (TME) features, and drug-response indicators. In the ER+ breast cancer cohort (defined by clinical ER annotation; PAM50 was used for molecular subtype stratification), differential expression, immune infiltration, drug–gene association analyses, and in vitro functional assays were performed. POSTN showed diagnostic and prognostic relevance in multiple cancer types and was associated with clinicopathological stage and molecular subtypes. POSTN expression correlated with TME-related features, particularly macrophages and cancer-associated fibroblasts (CAFs), and with immune-regulatory gene signatures. Drug–gene association analyses suggested that POSTN expression was related to differential predicted sensitivity/resistance to several small-molecule agents. Silencing POSTN reduced the migratory and invasive capacity of ER+ breast cancer cells. POSTN may serve as a candidate diagnostic and prognostic biomarker across cancers. In ER+ breast cancer, its expression is closely linked to stromal and immune features, supporting POSTN as a candidate microenvironment-associated biomarker with potential translational relevance.

KI fragen

Bookmark

View Full Paper